3.03
Schlusskurs vom Vortag:
$3.26
Offen:
$3.23
24-Stunden-Volumen:
420.90K
Relative Volume:
0.24
Marktkapitalisierung:
$325.48M
Einnahmen:
$42.51M
Nettoeinkommen (Verlust:
$-116.49M
KGV:
-2.7054
EPS:
-1.12
Netto-Cashflow:
$-120.82M
1W Leistung:
+1.68%
1M Leistung:
-12.68%
6M Leistung:
-65.25%
1J Leistung:
-76.18%
Tango Therapeutics Inc Stock (TNGX) Company Profile
Firmenname
Tango Therapeutics Inc
Sektor
Branche
Telefon
(857) 320-4900
Adresse
201 BROOKLINE AVENUE, BOSTON
Vergleichen Sie TNGX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TNGX
Tango Therapeutics Inc
|
3.03 | 325.48M | 42.51M | -116.49M | -120.82M | -1.12 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-07-17 | Eingeleitet | Jefferies | Buy |
2024-04-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
2024-02-12 | Eingeleitet | Piper Sandler | Overweight |
2023-12-08 | Eingeleitet | B. Riley Securities | Buy |
2022-10-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2021-09-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Tango Therapeutics Inc Aktie (TNGX) Neueste Nachrichten
What is Leerink Partnrs' Forecast for TNGX Q3 Earnings? - MarketBeat
Barbara Weber Sells 9,778 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat
Adam Crystal Sells 7,432 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock - MarketBeat
Tango Therapeutics Inc (NASDAQ: TNGX): Can A Stock Be -1.94% Lower Year-To-Date And Still Be A Loser? - Marketing Sentinel
One Tango Therapeutics Insider Raised Stake By 400% In Previous Year - Yahoo Finance
What is Leerink Partnrs’ Estimate for TNGX Q1 Earnings? - Defense World
Insider Selling: Tango Therapeutics, Inc. (NASDAQ:TNGX) CFO Sells 4,284 Shares of Stock - MarketBeat
What is Leerink Partnrs' Estimate for TNGX Q1 Earnings? - MarketBeat
Tango Therapeutics CFO Beckman sells $25,281 in stock - MSN
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock By Investing.com - Investing.com Canada
Tango Therapeutics executive sells shares worth $43,865 By Investing.com - Investing.com South Africa
Tango Therapeutics general counsel Barry Douglas sells $16,369 in stock - MSN
Tango Therapeutics CEO Barbara Weber sells $57,710 in stock - MSN
Is Tango Therapeutics Inc (TNGX) worth investing in despite its overvalued state? - US Post News
TNGX’s 2023 Market Dance: Up 8.41% – Time to Invest? - The InvestChronicle
Exclusive BAC Article: Tango Therapeutics; 2nd Half Of 2024 MTAP-Deletion Tumor Data TNG-908/TNG-462, TNG-260 Phase 1/2 Trial Advancement And Catalysts (NASDAQ:TNGX) - Seeking Alpha
TNGX (Tango Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
Tango Therapeutics Inc’s Market Journey: Closing Strong at 3.04, Up 4.47 - The Dwinnex
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $13.14 Average Price Target from Analysts - MarketBeat
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference - The Manila Times
Precision Cancer Medicine Pioneer Tango Therapeutics Takes Center Stage at Elite Biotech Conference - StockTitan
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Tango Therapeutics: Chance For A Short Squeeze - Seeking Alpha
Cantor Fitzgerald Estimates TNGX FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts TNGX FY2025 Earnings - MarketBeat
Tango Therapeutics' Stock Sinks To US$2.62, But Insiders Sold Even Lower - Simply Wall St
Barclays PLC Has $972,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics Highlights Breakthroughs in Cancer Treatment - TipRanks
Jane Street Group LLC Has $391,000 Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Rating of "Buy" by Analysts - MarketBeat
Franklin Resources Inc. Has $126,000 Stock Position in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Geode Capital Management LLC Has $10.54 Million Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Barclays PLC Raises Stake in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
State Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Purchased by State Street Corp - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $580,000 Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
The Manufacturers Life Insurance Company Cuts Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts - Investing.com India
Tango Therapeutics' SWOT analysis: stock outlook amid PRMT5 progress, pipeline shifts By Investing.com - Investing.com South Africa
TNGX Stock Hits 52-Week Low at $2.7 Amid Market Challenges - Investing.com UK
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cantor Fitzgerald Reaffirms Overweight Rating for Tango Therapeutics (NASDAQ:TNGX) - Defense World
Adaptive Biotechnologies Corp (ADPT) With A Potential Upside Of More Than -193.16% - Stocks Register
Unveiling 5 Analyst Insights On Tango Therapeutics - Benzinga
Is Tango Therapeutics (NASDAQ:TNGX) In A Good Position To Invest In Growth? - Simply Wall St
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 21.7% - MarketBeat
Finanzdaten der Tango Therapeutics Inc-Aktie (TNGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):